2022-10-26 16:00Financial Performance - The company's revenue for Q3 2022 reached ¥10,638,303,791.29, representing a 77.76% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥2,742,164,675.92, a significant increase of 209.11% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥2,382,204,909.91, reflecting a 143.31% increase compared to the previous year[5] - The company's revenue for the first three quarters of 2022 reached RMB 28,394.56 million, representing a year-on-year growth of 71.9%[11] - The net profit attributable to shareholders for the current reporting period was RMB 2,091.1 million, with a year-to-date net profit of RMB 1,071.2 million, reflecting improved capacity utilization and operational efficiency[11] - Total revenue for the first three quarters of 2022 reached ¥28.39 billion, a significant increase of 72% compared to ¥16.52 billion in the same period of 2021[27] - Net profit attributable to shareholders for the first three quarters of 2022 was ¥7.38 billion, up 74% from ¥3.56 billion in the same period of 2021[28] - Operating profit for the first three quarters of 2022 was ¥8.84 billion, an increase of 105% compared to ¥4.30 billion in the same period of 2021[27] - The company reported a significant increase in contract liabilities, which rose to RMB 3,959,048,700.05 from RMB 2,986,378,875.46, reflecting a growth of about 32.5%[26] Earnings and Shareholder Returns - The basic earnings per share for the quarter was ¥0.93, an increase of 210.00% year-over-year[6] - The diluted earnings per share was ¥0.81, reflecting a 170.00% increase compared to the same period last year[6] - The diluted earnings per share for the current reporting period was RMB 1.70, up from RMB 0.90 in the same period last year[11] - Basic earnings per share for the first three quarters of 2022 were ¥2.52, up from ¥1.22 in the same period of 2021[28] - The adjusted profit attributable to shareholders of the parent company for Q3 2022 was CNY 2,742,165 thousand, compared to CNY 887,126 thousand in Q3 2021, marking a growth of around 208.5%[37] - The company paid dividends amounting to CNY 1,529,442 thousand in the first three quarters of 2022, compared to CNY 892,980 thousand in the same period of 2021, representing an increase of about 71.4%[36] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥7,709,650,548.49, which is a 142.38% increase year-over-year[5] - The cash flow from operating activities for the year-to-date period was RMB 14,238 million, indicating strong cash generation capabilities[11] - The net cash generated from operating activities for the first three quarters of 2022 was CNY 7,430,657 thousand, a significant increase from CNY 3,069,256 thousand in the same period of 2021, representing a growth of approximately 142.5%[35] - The company reported a net cash outflow from investing activities of ¥6.11 billion for the first three quarters of 2022, compared to a net outflow of ¥4.27 billion in the same period of 2021[29] - The company reported a net cash outflow from investing activities of CNY 5,846,717 thousand for the first three quarters of 2022, compared to CNY 4,161,234 thousand in the same period of 2021, indicating an increase in investment expenditures[35] - The company’s cash flow from financing activities showed a net outflow of CNY 688,415 thousand in the first three quarters of 2022, compared to a net outflow of CNY 1,601,146 thousand in the same period of 2021, reflecting an improvement in financing cash flow[36] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥65,749,216,761.50, which is a 19.27% increase from the end of the previous year[6] - As of September 30, 2022, the total assets of the company reached RMB 65,749,216,761.50, an increase from RMB 55,127,388,384.03 at the end of 2021, representing a growth of approximately 19.0%[25] - The company's current assets totaled RMB 25,455,729,627.61, up from RMB 21,985,648,602.33 in the previous year, indicating a year-over-year increase of about 15.4%[25] - The total liabilities of the company were RMB 20,612,129,366.80, up from RMB 16,369,925,768.22, representing an increase of around 26.5%[26] - The equity attributable to shareholders reached RMB 44,810,034,664.07, compared to RMB 38,491,509,630.60, indicating a growth of approximately 16.5%[26] - The company’s long-term liabilities decreased to CNY 3,138,273 thousand as of September 30, 2022, from CNY 3,385,332 thousand at the end of 2021, showing a decline of approximately 7.3%[34] Business Operations and Growth - The company had 45,646 employees, with 13,488 holding a master's degree or higher, and 1,379 holding a doctoral degree or equivalent[4] - The company operates 32 operational bases globally, serving over 5,900 active clients from more than 30 countries[4] - The number of new customers exceeded 1,000, with active customers surpassing 5,900, indicating strong demand for the company's services globally[10] - Revenue from U.S. customers was RMB 18,991 million, a 110% increase year-on-year, while revenue from Chinese customers grew by 30% to RMB 5,318 million[10] - The chemical business segment generated RMB 20,816.66 million in revenue, a 106.6% increase compared to the same period last year, driven by significant growth in process development and production services[11] - The testing business segment achieved revenue of RMB 4,177.08 million, reflecting a year-on-year growth of 25.3%, with laboratory analysis and testing services growing by 35.2%[13] - The company continues to implement a "long-tail customer" strategy, with significant growth in long-tail customer performance observed in the first three quarters of 2022[11] - The company announced plans for a new base in Singapore and commenced construction of a new production facility in Middletown, Delaware, to better meet global partner needs[12] Research and Development - Research and development expenses increased to ¥1.09 billion, up 69% from ¥644 million in the same period of 2021[27] - Research and development expenses for Q3 2022 were RMB 432,068 thousand, up from RMB 239,775 thousand in Q3 2021[31] - The biology segment (WuXi Biology) achieved revenue of RMB 1,779.38 million, a year-on-year increase of 24.9% compared to RMB 1,424.33 million in the same period of 2021[14] - The cell and gene therapy CTDMO business (WuXi ATU) reported revenue of RMB 921.65 million, up 25.2% from RMB 735.93 million in 2021, with testing business revenue growing by 44% and process development revenue increasing by 54%[15] - The domestic new drug development services unit (WuXi DDSU) generated revenue of RMB 671.80 million, a decline of 27.9% from RMB 931.80 million in the same period last year, primarily due to business upgrades to meet higher client demands[17] - The company completed 15 IND applications and received 26 clinical trial approvals in 2022, with a total of 159 IND applications and 136 clinical trial approvals by the end of Q3 2022[17] - The biology segment's revenue from new molecular types and biopharmaceuticals grew by 76% year-on-year, increasing its contribution to total biology revenue from 14.6% in 2021 to 20.5% in the first three quarters of 2022[14] - The company is currently working on 15 new molecular type preclinical projects, with several expected to submit IND applications by the end of 2022 or early 2023[17] - The company has 38 TESSA™ projects under client evaluation, including collaborations with six major biotech/pharmaceutical companies[16] - The TESSA™ technology, launched in March 2022, allows for the production of AAV at a scale of 200L, which is over ten times more efficient than traditional plasmid-based methods[15]